Full title: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial):An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations.Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Age: 18+
Locations:
- Birmingham – University Hospital Birmingham
- Bristol – Bristol Haematology and Oncology Centre
- Cardiff – Velindre Cancer Centre
- Edinburgh – Western General Hospital
- Glasgow – The Beatson Hospital
- Leicester – Leicester Royal Infirmary
- London – Royal Marsden Hospital, University College London Hospital, Guy’s Hospital
- Manchester – The Christie Hospital
- Newcastle – Freeman Hospital
- Oxford – Churchill Hospital
- Sheffield – Western Park Hospital
- Southampton – Southampton General Hospital
- Wirral – Clatterbridge Cancer Centre
Brief summary:
The DETERMINE study is a UK study exploring whether existing cancer drugs can be used in other types of cancer. This includes looking at a drug called Capmatinib, which is currently used to treat lung cancers with an MET change to see if it also effective in treating sarcomas with a similar MET change.
More information can be found at clinicaltrials.gov and cancerresearchuk.org
To find out more about this trial and whether you could take part, talk to your clinical team.
